Your Baby’s Monthly Milestones
NYU Langone pediatrician Dr. Robin S. Jacobson spoke to POPSUGAR about exciting developmental milestones in a baby’s first year of life.
Your Child May Not Need a Tonsillectomy After All
Experts at NYU Langone Hospital—Brooklyn explain why tonsillectomies are no longer a routine part of childhood.
YouTube Is Unreliable for Information on Prostate Cancer
Popular YouTube videos on prostate cancer often present misleading and potentially dangerous information according to a new NYU Langone study.
Adult Cardiac Surgery | NYU Langone Health
NYU Langone’s cardiac surgeons perform heart surgery, including heart valve procedures, for adults with heart-related conditions.
NYU Langone Transplant Institute | NYU Langone Health
Experts at the NYU Langone Transplant Institute specialize in heart, kidney, liver, lung, and pancreas transplantation.
Obstetrics & Gynecology | NYU Langone Health
At NYU Langone, our obstetrician–gynecologists provide experienced and compassionate care to people of all ages and gender identities.
24-Hour Activity and Cardiometabolic Health in Chinese American Women with a History of Gestational Diabetes
Chinese Americans, one of the largest and fastest-growing minority groups in the US, have an increased risk for type 2 diabetes (T2D) and a substantial burden related to T2D. Moreover, Chinese American women experience high rates of gestational diabetes (GD). However, little is known about the 24-hour activity (physical activity, sedentary behavior, sleep) and cardiometabolic health of Chinese American women with a history of GD. The objectives of this mixed methods study are to characterize the 24-hour activity and cardiometabolic risk profile and to describe the multi-contextual barriers and facilitators to meeting physical activity and sleep guidelines in this high-risk population. This pilot feasibility study using a convergent mixed methods design will collect accelerometer-based data, surveys, biomarker data, and conduct in-depth interviews with a sample of 56 Chinese American women with a history of GD in the past 0.5 - 5 years. Participants (n=56) will be recruited from NYU Langone Health System, online via WeChat (a Chinese social media app), and in person in Chinese community centers. Accelerometers (Actigraph GT9X+) will be used to collect 7 consecutive days of 24-hour activity. Validated instruments (online) will be used to assess psychological, social, cultural, and environmental characteristics. Biomarker data (glucose regulation and lipid profile) collection and in-depth interviews will be conducted in person. Descriptive analysis will be used to describe the sample, their 24-hour activity pattern, and their cardiometabolic risk profile. Quantitative and qualitative data will be integrated in the final analytic stage to identify modifiable factors for meeting physical activity and sleep guidelines.In addition,
3D Free-Breathing Fat and Iron Corrected T1 Mapping
This study proposes a novel 3D liver T1 mapping technique that will enable water-specific T1 mapping (or fat/iron-corrected T1 mapping) to remove the influence of both fat and iron, two confounding factors that have typically been neglected in standard T1 mapping. In a pilot study, we will test the performance of the proposed method for evaluating nonalcoholic steatohepatitis (NASH).
A 12-week randomized double-blind placebo-controlled trial investigating the effects of Levetiracetam in early psychosis
This is a 12-week study of levetiracetam in conjunction with a second generation antipsychotic in early psychosis patients with treatment-resistant symptoms. Treatment with antipsychotics has been shown to be associated with loss of volume in the hippocampus. Brain chemicals, called neurotransmitters, that might be associated with this loss are glutamate and dopamine. The drug levetiracetam reduces excessive amounts of these neurotransmitters, which may help protect against this loss when taken with antipsychotics. Participants will complete screening and baseline visits before being randomized in a 2:1 ratio of levetiracetam or placebo. They will complete weekly study visits for the first 4 weeks (Baseline, Weeks 2-4) and then additional visits at Week 6, 8, and 12. Participants will be studied both by assessing change in symptom severity and cognitive performance over the 12 weeks as well as using a measure of Hippocampal Volume Integrity at baseline and week 12. After completing Week 12 or decision to withdraw prematurely from the study, participants will complete a 9 day medication tapering regimen.
A 2-Part Seamless Part A (Phase 2)/Part B (Phase 3) Randomized Double-Blind Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of BIIB059 in Participants with Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cutaneous Lupus Erythematosus with or without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy (AMETHYST)
This is a 2-part seamless, randomized, double-blind, placebo-controlled, multicenter, Phase 2/3 study designed to evaluate the efficacy and safety of BIIB059 for the treatment of participants with active SCLE and/or CCLE with or without systemic manifestations and refractory and/or intolerant to antimalarial therapy. The study includes a Part A (Phase 2) and a Part B (Phase 3 registrational). The study comprises a 24-week DBPC treatment period followed by a 28-week ETP; the total treatment duration of 52 weeks.Participants who successfully complete the 52-week treatment period will be offered the opportunity to participate in an LTE study under a separate protocol. The LTE study will evaluate the long-term safety profile of BIIB059 in the treatment of CLE.Participants will be randomly assigned in a 2:1 ratio to receive either BIIB059 or placebo SC Q4W, respectively, from Week 0 to Week 20, with an additional loading dose at Week 2 during the DBPC period.During the ETP, all participants will receive BIIB059 from Week 24 to Week 48. At Week 26, participants will receive a loading dose where all participants who were randomly assigned to BIIB059 during the DBPC period will receive the placebo and all participants who were randomly assigned to placebo during the DBPC period will receive BIIB059.